| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| B7-H1 Antigen | 14 | 2022 | 1055 | 1.390 |
Why?
|
| Tumor Escape | 6 | 2021 | 248 | 0.840 |
Why?
|
| Breast Neoplasms | 31 | 2022 | 16172 | 0.540 |
Why?
|
| Receptor, ErbB-2 | 15 | 2019 | 2641 | 0.520 |
Why?
|
| Gene Expression Regulation, Neoplastic | 19 | 2021 | 9078 | 0.510 |
Why?
|
| ErbB Receptors | 9 | 2018 | 2372 | 0.480 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2022 | 1345 | 0.390 |
Why?
|
| Cell Line, Tumor | 30 | 2022 | 14869 | 0.350 |
Why?
|
| Phosphorylation | 18 | 2019 | 4986 | 0.350 |
Why?
|
| Ribonuclease, Pancreatic | 2 | 2021 | 58 | 0.340 |
Why?
|
| Mice, Inbred BALB C | 15 | 2021 | 2473 | 0.340 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 3 | 2019 | 162 | 0.330 |
Why?
|
| Carcinogenesis | 3 | 2021 | 1030 | 0.320 |
Why?
|
| Mice | 46 | 2022 | 35975 | 0.320 |
Why?
|
| Adenovirus E1A Proteins | 6 | 2009 | 161 | 0.300 |
Why?
|
| T-Lymphocytes | 4 | 2022 | 3928 | 0.290 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 2019 | 557 | 0.280 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2019 | 263 | 0.270 |
Why?
|
| Animals | 49 | 2022 | 62826 | 0.260 |
Why?
|
| Signal Transduction | 17 | 2019 | 12204 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 5 | 2022 | 4511 | 0.250 |
Why?
|
| Mouth Neoplasms | 3 | 1999 | 731 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2016 | 2093 | 0.240 |
Why?
|
| Receptors, Eph Family | 2 | 2022 | 32 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2020 | 2617 | 0.240 |
Why?
|
| Immunologic Surveillance | 3 | 2018 | 61 | 0.230 |
Why?
|
| Twist-Related Protein 1 | 2 | 2016 | 132 | 0.220 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2020 | 685 | 0.220 |
Why?
|
| Mice, Nude | 14 | 2021 | 4355 | 0.220 |
Why?
|
| Neoplasm Proteins | 5 | 2019 | 3352 | 0.210 |
Why?
|
| Cell Proliferation | 10 | 2020 | 7295 | 0.210 |
Why?
|
| RNA, Long Noncoding | 2 | 2019 | 618 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2016 | 1617 | 0.210 |
Why?
|
| Neoplasms | 9 | 2022 | 15835 | 0.210 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2018 | 1086 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2022 | 66 | 0.200 |
Why?
|
| Galectins | 1 | 2022 | 73 | 0.200 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2018 | 1004 | 0.200 |
Why?
|
| Ephrin-A4 | 1 | 2021 | 7 | 0.190 |
Why?
|
| Neoplastic Stem Cells | 2 | 2021 | 1469 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2019 | 3656 | 0.190 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2020 | 2154 | 0.190 |
Why?
|
| Ribonucleases | 1 | 2020 | 99 | 0.180 |
Why?
|
| Cell Adhesion | 2 | 2013 | 1045 | 0.180 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2021 | 207 | 0.180 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2021 | 247 | 0.180 |
Why?
|
| Pyroptosis | 1 | 2020 | 29 | 0.180 |
Why?
|
| NF-kappa B | 4 | 2016 | 1582 | 0.180 |
Why?
|
| Ubiquitination | 6 | 2019 | 577 | 0.180 |
Why?
|
| Neoplasms, Experimental | 3 | 2019 | 791 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2014 | 527 | 0.170 |
Why?
|
| Cell Death | 1 | 2022 | 689 | 0.170 |
Why?
|
| Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase | 1 | 2019 | 20 | 0.170 |
Why?
|
| Humans | 70 | 2022 | 270836 | 0.170 |
Why?
|
| Receptor, ErbB-3 | 1 | 1999 | 126 | 0.170 |
Why?
|
| Protein Stability | 5 | 2019 | 374 | 0.160 |
Why?
|
| Lipoylation | 1 | 2018 | 9 | 0.160 |
Why?
|
| RNA, Neoplasm | 2 | 2017 | 812 | 0.160 |
Why?
|
| Antineoplastic Agents | 9 | 2022 | 14675 | 0.160 |
Why?
|
| Repressor Proteins | 4 | 2017 | 1724 | 0.160 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2019 | 37 | 0.160 |
Why?
|
| Thiolester Hydrolases | 1 | 2019 | 36 | 0.160 |
Why?
|
| Protein Kinase C-delta | 1 | 2018 | 42 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2022 | 3917 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 15 | 2020 | 5827 | 0.160 |
Why?
|
| Acyltransferases | 1 | 2018 | 66 | 0.160 |
Why?
|
| Zinc Finger Protein GLI1 | 2 | 2016 | 115 | 0.160 |
Why?
|
| Janus Kinase 1 | 1 | 2019 | 125 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 5404 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2021 | 1804 | 0.160 |
Why?
|
| Hexosyltransferases | 1 | 2018 | 14 | 0.160 |
Why?
|
| Oncogenes | 2 | 2019 | 700 | 0.160 |
Why?
|
| Transcription Activator-Like Effector Nucleases | 1 | 2018 | 6 | 0.160 |
Why?
|
| Antigen Presentation | 1 | 2019 | 289 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2019 | 253 | 0.150 |
Why?
|
| RecQ Helicases | 1 | 2018 | 97 | 0.150 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 513 | 0.150 |
Why?
|
| Immune Evasion | 1 | 2018 | 76 | 0.150 |
Why?
|
| Female | 47 | 2022 | 148425 | 0.150 |
Why?
|
| Human Embryonic Stem Cells | 1 | 2018 | 32 | 0.150 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2018 | 405 | 0.150 |
Why?
|
| Specimen Handling | 1 | 2019 | 311 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 3 | 2021 | 5219 | 0.140 |
Why?
|
| Transcription Factors | 4 | 2012 | 5489 | 0.140 |
Why?
|
| Apoptosis | 8 | 2020 | 7848 | 0.140 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2022 | 508 | 0.140 |
Why?
|
| DNA Methylation | 2 | 2017 | 2736 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 397 | 0.140 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2017 | 97 | 0.140 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2018 | 219 | 0.130 |
Why?
|
| Immunohistochemistry | 7 | 2022 | 7816 | 0.130 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2017 | 163 | 0.130 |
Why?
|
| Liver Neoplasms | 3 | 2020 | 4773 | 0.130 |
Why?
|
| Antibodies | 1 | 2019 | 837 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 1010 | 0.130 |
Why?
|
| Transfection | 12 | 2016 | 3167 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2020 | 1836 | 0.130 |
Why?
|
| Genetic Therapy | 6 | 2011 | 1731 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2019 | 429 | 0.130 |
Why?
|
| Exosomes | 1 | 2018 | 252 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 4946 | 0.130 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2017 | 221 | 0.130 |
Why?
|
| Gene Editing | 1 | 2018 | 230 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2019 | 815 | 0.120 |
Why?
|
| I-kappa B Kinase | 3 | 2012 | 250 | 0.120 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 10696 | 0.120 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 744 | 0.120 |
Why?
|
| Peptide Hydrolases | 1 | 2016 | 264 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2019 | 1075 | 0.120 |
Why?
|
| Sirtuins | 1 | 2014 | 43 | 0.120 |
Why?
|
| Metformin | 1 | 2018 | 395 | 0.120 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 666 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 774 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 1999 | 5566 | 0.120 |
Why?
|
| DNA-Binding Proteins | 2 | 2020 | 5039 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2018 | 2465 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 1725 | 0.120 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2011 | 191 | 0.110 |
Why?
|
| Transcriptional Activation | 3 | 2018 | 1145 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 617 | 0.110 |
Why?
|
| Glycosylation | 3 | 2019 | 231 | 0.110 |
Why?
|
| Adenocarcinoma | 4 | 2018 | 7933 | 0.110 |
Why?
|
| HEK293 Cells | 4 | 2021 | 1472 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 1015 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2019 | 2467 | 0.110 |
Why?
|
| Mediator Complex | 1 | 2013 | 62 | 0.110 |
Why?
|
| Mammary Glands, Animal | 3 | 2010 | 635 | 0.110 |
Why?
|
| Argonaute Proteins | 1 | 2013 | 42 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 1292 | 0.110 |
Why?
|
| TNF Receptor-Associated Factor 4 | 1 | 2013 | 24 | 0.110 |
Why?
|
| Glycolysis | 1 | 2016 | 532 | 0.110 |
Why?
|
| Janus Kinase 2 | 1 | 2017 | 753 | 0.110 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 272 | 0.100 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 352 | 0.100 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2011 | 39 | 0.100 |
Why?
|
| Nuclear Proteins | 3 | 2013 | 3457 | 0.100 |
Why?
|
| Breast | 3 | 2016 | 1363 | 0.100 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 135 | 0.100 |
Why?
|
| Cytidine Deaminase | 1 | 2011 | 85 | 0.100 |
Why?
|
| Cytosine Deaminase | 1 | 2011 | 43 | 0.100 |
Why?
|
| MCF-7 Cells | 3 | 2019 | 553 | 0.100 |
Why?
|
| Pentosyltransferases | 1 | 2011 | 26 | 0.100 |
Why?
|
| Endostatins | 1 | 2011 | 48 | 0.100 |
Why?
|
| Cell Nucleus | 3 | 2018 | 1742 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 360 | 0.100 |
Why?
|
| Neoplasm Transplantation | 5 | 2018 | 1565 | 0.090 |
Why?
|
| Tumor Microenvironment | 5 | 2022 | 2978 | 0.090 |
Why?
|
| Cell Survival | 4 | 2022 | 3078 | 0.090 |
Why?
|
| Protein Binding | 6 | 2021 | 3534 | 0.090 |
Why?
|
| Trans-Activators | 3 | 2009 | 1651 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 5 | 2010 | 3243 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2013 | 487 | 0.090 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2013 | 384 | 0.090 |
Why?
|
| MicroRNAs | 3 | 2013 | 2904 | 0.090 |
Why?
|
| Receptor, Notch1 | 1 | 2011 | 220 | 0.090 |
Why?
|
| Prognosis | 10 | 2018 | 22421 | 0.090 |
Why?
|
| Down-Regulation | 3 | 2019 | 2108 | 0.090 |
Why?
|
| RNA Helicases | 1 | 2010 | 103 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 1598 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2013 | 492 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2018 | 2953 | 0.080 |
Why?
|
| Cell Cycle Proteins | 2 | 2013 | 2123 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2017 | 1570 | 0.080 |
Why?
|
| RNA, Messenger | 4 | 2013 | 6493 | 0.080 |
Why?
|
| Hedgehog Proteins | 1 | 2012 | 441 | 0.080 |
Why?
|
| DNA Replication | 1 | 2013 | 771 | 0.080 |
Why?
|
| Disease Progression | 5 | 2019 | 6887 | 0.080 |
Why?
|
| Histones | 1 | 2016 | 1510 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 1547 | 0.080 |
Why?
|
| Tyrosine | 3 | 2022 | 510 | 0.080 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 4966 | 0.080 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2008 | 72 | 0.080 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2013 | 528 | 0.080 |
Why?
|
| Hepatitis B virus | 1 | 2009 | 223 | 0.080 |
Why?
|
| Mammary Glands, Human | 2 | 2019 | 185 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 366 | 0.070 |
Why?
|
| Epidermal Growth Factor | 2 | 2016 | 445 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 196 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2004 | 896 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 5306 | 0.070 |
Why?
|
| HeLa Cells | 3 | 2018 | 1716 | 0.070 |
Why?
|
| Genes, p53 | 1 | 2011 | 1135 | 0.070 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 2 | 2016 | 40 | 0.070 |
Why?
|
| Cell Division | 5 | 2004 | 2715 | 0.070 |
Why?
|
| Epithelial Cells | 3 | 2018 | 1887 | 0.070 |
Why?
|
| Telomerase | 1 | 2009 | 533 | 0.070 |
Why?
|
| Ovarian Neoplasms | 4 | 2009 | 4762 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 2 | 2008 | 887 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2018 | 912 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2021 | 3655 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 2 | 1999 | 4126 | 0.060 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 5160 | 0.060 |
Why?
|
| Mice, Transgenic | 4 | 2019 | 4368 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2021 | 1084 | 0.060 |
Why?
|
| Paclitaxel | 2 | 2004 | 2096 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2019 | 5836 | 0.060 |
Why?
|
| Cell Line | 5 | 2021 | 5433 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 1062 | 0.060 |
Why?
|
| Enzyme Inhibitors | 3 | 2001 | 1985 | 0.060 |
Why?
|
| Stem Cells | 1 | 2011 | 1229 | 0.060 |
Why?
|
| Cyclin D1 | 2 | 2010 | 589 | 0.060 |
Why?
|
| Benzamides | 2 | 2019 | 1883 | 0.060 |
Why?
|
| Cell Movement | 3 | 2016 | 2500 | 0.060 |
Why?
|
| Melanoma | 1 | 2020 | 5522 | 0.060 |
Why?
|
| Immunotherapy | 3 | 2022 | 3528 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 3392 | 0.050 |
Why?
|
| Positive Transcriptional Elongation Factor B | 1 | 2022 | 37 | 0.050 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2001 | 21 | 0.050 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2001 | 22 | 0.050 |
Why?
|
| DNA | 1 | 2010 | 3071 | 0.050 |
Why?
|
| Genetic Vectors | 5 | 2011 | 1882 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2022 | 7457 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2013 | 3650 | 0.050 |
Why?
|
| Anoikis | 1 | 2001 | 63 | 0.050 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2001 | 58 | 0.050 |
Why?
|
| Ubiquitins | 1 | 2001 | 100 | 0.050 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2001 | 97 | 0.050 |
Why?
|
| AC133 Antigen | 1 | 2021 | 109 | 0.050 |
Why?
|
| Mice, Inbred A | 1 | 2020 | 33 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2013 | 9309 | 0.050 |
Why?
|
| Pyridines | 1 | 2008 | 1310 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2022 | 1335 | 0.050 |
Why?
|
| CD146 Antigen | 1 | 2020 | 57 | 0.050 |
Why?
|
| Cell Migration Assays | 1 | 2020 | 10 | 0.050 |
Why?
|
| Lactation Disorders | 1 | 2000 | 10 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 324 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 4980 | 0.050 |
Why?
|
| 3T3 Cells | 4 | 2001 | 388 | 0.040 |
Why?
|
| Growth Inhibitors | 1 | 2000 | 164 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2006 | 1150 | 0.040 |
Why?
|
| Receptor, ErbB-4 | 1 | 1999 | 23 | 0.040 |
Why?
|
| Brain | 1 | 2013 | 4253 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2021 | 917 | 0.040 |
Why?
|
| Indolizines | 1 | 2019 | 46 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2001 | 1117 | 0.040 |
Why?
|
| Pyridinium Compounds | 1 | 2019 | 64 | 0.040 |
Why?
|
| Adult | 9 | 2018 | 81477 | 0.040 |
Why?
|
| Male | 10 | 2020 | 128405 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2019 | 54 | 0.040 |
Why?
|
| Cyclic N-Oxides | 1 | 2019 | 98 | 0.040 |
Why?
|
| Middle Aged | 9 | 2021 | 89906 | 0.040 |
Why?
|
| Emodin | 1 | 1999 | 15 | 0.040 |
Why?
|
| Cyclins | 1 | 2001 | 469 | 0.040 |
Why?
|
| A549 Cells | 1 | 2019 | 127 | 0.040 |
Why?
|
| Palmitates | 1 | 2018 | 23 | 0.040 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2000 | 179 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 747 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 293 | 0.040 |
Why?
|
| Transplantation, Heterologous | 3 | 2011 | 1088 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2019 | 318 | 0.040 |
Why?
|
| Biomarkers | 2 | 2022 | 5105 | 0.040 |
Why?
|
| Granzymes | 1 | 2019 | 95 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2019 | 357 | 0.040 |
Why?
|
| Pyrrolidinones | 1 | 2019 | 62 | 0.040 |
Why?
|
| Benzylidene Compounds | 1 | 2018 | 9 | 0.040 |
Why?
|
| Necrosis | 1 | 2020 | 605 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2001 | 718 | 0.040 |
Why?
|
| Genes, Viral | 1 | 1999 | 255 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2020 | 165 | 0.040 |
Why?
|
| Endoplasmic Reticulum-Associated Degradation | 1 | 2018 | 35 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 192 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2019 | 259 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 3234 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 7209 | 0.040 |
Why?
|
| Aged | 8 | 2018 | 73010 | 0.040 |
Why?
|
| Triazines | 1 | 2019 | 123 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2018 | 93 | 0.040 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2018 | 48 | 0.040 |
Why?
|
| Morpholines | 1 | 2019 | 297 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 118 | 0.040 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2018 | 126 | 0.040 |
Why?
|
| Ligands | 1 | 2020 | 1060 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2001 | 916 | 0.040 |
Why?
|
| beta Catenin | 2 | 2018 | 689 | 0.040 |
Why?
|
| Mutation | 4 | 2018 | 15828 | 0.040 |
Why?
|
| U937 Cells | 1 | 2017 | 179 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2018 | 132 | 0.040 |
Why?
|
| Binding Sites | 2 | 2018 | 2305 | 0.040 |
Why?
|
| Hypoxia | 1 | 2020 | 467 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2000 | 542 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2004 | 451 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2017 | 259 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 879 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 171 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 361 | 0.040 |
Why?
|
| Gene Expression Regulation | 3 | 2010 | 4180 | 0.040 |
Why?
|
| Recombinant Proteins | 5 | 2001 | 3076 | 0.040 |
Why?
|
| Serine | 1 | 2018 | 397 | 0.040 |
Why?
|
| Receptors, Progesterone | 2 | 2019 | 1642 | 0.040 |
Why?
|
| COP9 Signalosome Complex | 1 | 2016 | 79 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2018 | 336 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2018 | 206 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 671 | 0.030 |
Why?
|
| Cattle | 1 | 2018 | 846 | 0.030 |
Why?
|
| Aerobiosis | 1 | 2016 | 32 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2001 | 1885 | 0.030 |
Why?
|
| Catalysis | 1 | 2016 | 246 | 0.030 |
Why?
|
| Cytosol | 1 | 2016 | 271 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 3646 | 0.030 |
Why?
|
| Pyruvate Kinase | 1 | 2016 | 34 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2018 | 384 | 0.030 |
Why?
|
| Curcumin | 1 | 2016 | 119 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2001 | 1008 | 0.030 |
Why?
|
| Heterografts | 1 | 2018 | 744 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 530 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 487 | 0.030 |
Why?
|
| Cetuximab | 1 | 2017 | 473 | 0.030 |
Why?
|
| Homozygote | 1 | 2018 | 755 | 0.030 |
Why?
|
| Quinolines | 1 | 2019 | 402 | 0.030 |
Why?
|
| Heterozygote | 1 | 2018 | 1033 | 0.030 |
Why?
|
| Stilbenes | 1 | 2016 | 94 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 4068 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 625 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2016 | 154 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 401 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 30874 | 0.030 |
Why?
|
| Base Sequence | 3 | 2011 | 5498 | 0.030 |
Why?
|
| RNA Interference | 1 | 2018 | 1398 | 0.030 |
Why?
|
| Antigens, Neoplasm | 2 | 2017 | 1589 | 0.030 |
Why?
|
| Adenoma | 1 | 2019 | 741 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 782 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 1857 | 0.030 |
Why?
|
| Genetic Markers | 1 | 1997 | 1015 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2019 | 5785 | 0.030 |
Why?
|
| Proteolysis | 1 | 2016 | 380 | 0.030 |
Why?
|
| Minichromosome Maintenance Complex Component 7 | 1 | 2013 | 14 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 2013 | 125 | 0.030 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2013 | 40 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 1024 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2019 | 995 | 0.030 |
Why?
|
| Proteins | 1 | 2001 | 2047 | 0.030 |
Why?
|
| Models, Biological | 2 | 2012 | 3225 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 155 | 0.030 |
Why?
|
| Integrin beta1 | 1 | 2013 | 134 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 1059 | 0.030 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2013 | 70 | 0.030 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2013 | 163 | 0.030 |
Why?
|
| RNA Precursors | 1 | 2013 | 125 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2013 | 306 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 594 | 0.030 |
Why?
|
| APOBEC-3G Deaminase | 1 | 2011 | 5 | 0.030 |
Why?
|
| Protein Biosynthesis | 2 | 2009 | 1036 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 2013 | 305 | 0.030 |
Why?
|
| Ribonuclease III | 1 | 2013 | 188 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 6243 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 6164 | 0.020 |
Why?
|
| Consensus Sequence | 2 | 2001 | 120 | 0.020 |
Why?
|
| Macrophages | 1 | 2018 | 1369 | 0.020 |
Why?
|
| Patient Selection | 1 | 2019 | 2042 | 0.020 |
Why?
|
| Endopeptidases | 1 | 2013 | 233 | 0.020 |
Why?
|
| Quinazolines | 1 | 2016 | 951 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2014 | 735 | 0.020 |
Why?
|
| Entosis | 1 | 2011 | 4 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 1737 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 1158 | 0.020 |
Why?
|
| Cytokinesis | 1 | 2011 | 57 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 261 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2004 | 9036 | 0.020 |
Why?
|
| Histone Deacetylase 2 | 1 | 2009 | 36 | 0.020 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2009 | 58 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 475 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1980 | 3058 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2011 | 378 | 0.020 |
Why?
|
| Prodrugs | 1 | 2011 | 226 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2010 | 320 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1212 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2009 | 98 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2009 | 185 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2021 | 33796 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2009 | 196 | 0.020 |
Why?
|
| Protein Transport | 2 | 2001 | 738 | 0.020 |
Why?
|
| Sp1 Transcription Factor | 1 | 2009 | 193 | 0.020 |
Why?
|
| Gene Expression | 3 | 2001 | 3681 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2008 | 63 | 0.020 |
Why?
|
| Mitosis | 1 | 2011 | 690 | 0.020 |
Why?
|
| DNA Primers | 2 | 2001 | 1508 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2397 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2011 | 706 | 0.020 |
Why?
|
| beta-Galactosidase | 2 | 1999 | 278 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2013 | 2150 | 0.020 |
Why?
|
| Adolescent | 2 | 1999 | 32578 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 2212 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2008 | 644 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2009 | 3415 | 0.020 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2008 | 288 | 0.020 |
Why?
|
| Niacinamide | 1 | 2008 | 428 | 0.020 |
Why?
|
| Genes, Reporter | 2 | 1999 | 831 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 1667 | 0.020 |
Why?
|
| United States | 1 | 2022 | 15964 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2009 | 843 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 601 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 1575 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2012 | 2126 | 0.010 |
Why?
|
| Adenoviridae | 2 | 2001 | 1509 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 11741 | 0.010 |
Why?
|
| Rats | 1 | 2012 | 6659 | 0.010 |
Why?
|
| Receptors, Estrogen | 2 | 2001 | 2263 | 0.010 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2001 | 11 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 7929 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2001 | 6789 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2001 | 48 | 0.010 |
Why?
|
| Inflammation | 1 | 2012 | 2526 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2001 | 101 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 2001 | 58 | 0.010 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2001 | 98 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 2001 | 78 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2001 | 380 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 811 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2001 | 431 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 5501 | 0.010 |
Why?
|
| Injections | 1 | 2001 | 289 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2001 | 228 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2001 | 321 | 0.010 |
Why?
|
| Thymidine | 1 | 2000 | 169 | 0.010 |
Why?
|
| Prolactin | 1 | 2000 | 174 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2000 | 244 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2001 | 414 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2001 | 298 | 0.010 |
Why?
|
| Thorax | 1 | 2001 | 230 | 0.010 |
Why?
|
| Growth Hormone | 1 | 2000 | 227 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 22014 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2001 | 539 | 0.010 |
Why?
|
| Etoposide | 1 | 2001 | 902 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2001 | 505 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2001 | 686 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 711 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2001 | 1757 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2000 | 261 | 0.010 |
Why?
|
| Survival Rate | 2 | 2004 | 12488 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2001 | 624 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1980 | 444 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2000 | 634 | 0.010 |
Why?
|
| Iron | 1 | 2001 | 378 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2000 | 616 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 2250 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2001 | 532 | 0.010 |
Why?
|
| Cholesterol | 1 | 2001 | 679 | 0.010 |
Why?
|
| Pregnancy | 2 | 2001 | 8038 | 0.010 |
Why?
|
| Progesterone | 1 | 2000 | 730 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2000 | 493 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2001 | 495 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1997 | 269 | 0.010 |
Why?
|
| Estradiol | 1 | 2000 | 885 | 0.010 |
Why?
|
| Ovary | 1 | 2000 | 701 | 0.010 |
Why?
|
| Uterus | 1 | 2001 | 807 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 1837 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 1997 | 191 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1999 | 621 | 0.010 |
Why?
|
| Chromatin | 1 | 2001 | 1047 | 0.010 |
Why?
|
| Body Weight | 1 | 2000 | 1337 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1997 | 885 | 0.010 |
Why?
|
| Child | 1 | 1997 | 30422 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1999 | 1367 | 0.010 |
Why?
|
| Epitopes | 1 | 1997 | 710 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2001 | 1465 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2001 | 1666 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 1539 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1997 | 39626 | 0.010 |
Why?
|
| DNA Damage | 1 | 2001 | 1974 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 1997 | 734 | 0.010 |
Why?
|
| Cytokines | 1 | 2001 | 2836 | 0.010 |
Why?
|
| Virus Replication | 1 | 1995 | 759 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1980 | 4963 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1997 | 4643 | 0.010 |
Why?
|
| Carcinoma | 1 | 2001 | 2627 | 0.010 |
Why?
|
| Phenotype | 1 | 2000 | 6454 | 0.010 |
Why?
|
| Time Factors | 1 | 2000 | 13122 | 0.000 |
Why?
|